Literature DB >> 15641884

Rhabdomyolysis and coma associated with amisulpride: a probable atypical presentation of neuroleptic malignant syndrome.

E Cem Atbasoglu, Halise Devrimci Ozguven, Meram Can Saka, Ceren Goker.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15641884     DOI: 10.4088/jcp.v65n1219f

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


× No keyword cloud information.
  7 in total

1.  Acute rhabdomyolysis during treatment with amisulpride and metformin.

Authors:  Francesco Ursini; Elena Succurro; Alessandro Grembiale; Franco Arturi
Journal:  Eur J Clin Pharmacol       Date:  2009-12-18       Impact factor: 2.953

2.  [Malignant neuroleptic syndrome associated with amisulpride].

Authors:  C Harter; C Obier; K-F Druschky; B Eikelmann
Journal:  Nervenarzt       Date:  2008-01       Impact factor: 1.214

Review 3.  Neuroleptic malignant syndrome associated with atypical antipsychotic drugs.

Authors:  Julian N Trollor; Xiaohua Chen; Perminder S Sachdev
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

4.  Lethal neuroleptic malignant syndrome due to amisulpride.

Authors:  Frank Musshoff; Elke Doberentz; Burkhard Madea
Journal:  Forensic Sci Med Pathol       Date:  2013-03-16       Impact factor: 2.007

Review 5.  Second-generation antipsychotics and neuroleptic malignant syndrome: systematic review and case report analysis.

Authors:  Martino Belvederi Murri; Argentina Guaglianone; Michele Bugliani; Pietro Calcagno; Matteo Respino; Gianluca Serafini; Marco Innamorati; Maurizio Pompili; Mario Amore
Journal:  Drugs R D       Date:  2015-03

6.  Video of dantrolene effectiveness on neuroleptic malignant syndrome associated muscular rigidity and tremor.

Authors:  Miran Brvar; Matjaz Bunc
Journal:  Crit Care       Date:  2007       Impact factor: 9.097

Review 7.  Neuroleptic Malignant Syndrome: A Review from a Clinically Oriented Perspective.

Authors:  Lurdes Tse; Alasdair M Barr; Vanessa Scarapicchia; Fidel Vila-Rodriguez
Journal:  Curr Neuropharmacol       Date:  2015       Impact factor: 7.363

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.